Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes.
Article Details
- CitationCopy to clipboard
Scherer K, Studer W, Figueiredo V, Bircher AJ
Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes.
Ann Allergy Asthma Immunol. 2006 Mar;96(3):497-500.
- PubMed ID
- 16597088 [ View in PubMed]
- Abstract
BACKGROUND: Blue dyes used for lymphatic mapping in sentinel lymph node biopsy cause intraoperative anaphylactic reactions in up to 2.7% of patients. With increasing implementation of this technique, the incidence of anaphylaxis to these dyes can be expected to increase. In the literature, the chemically often unrelated and inconsistently designated dyes have been confused, adding to other inconsistencies in the nomenclature. OBJECTIVE: To demonstrate the nomenclature, chemical and physiologic differences, and allergenicity of the various blue dyes used in a medical context. METHODS: We describe a patient with an intraoperative grade IV anaphylactic reaction to isosulfan blue. Immediate-type hypersensitivity was proved by positive skin test reactions and CD63 expression to isosulfan blue and cross-reactivity to patent blue V. RESULTS: A review of the literature clarified the exact nomenclature of the blue dyes and the possible pitfalls of confusing nomenclature in the context of structurally closely related dyes with different allergenic properties. For the detection of type I hypersensitivity, intracutaneous tests are valuable tools. An IgE-mediated mechanism has been shown recently. In most cases, sensitization exists without known previous exposure in a medical context. This may be due to the widespread use of such dyes in objects of everyday life. Preoperative antiallergic medication use does not prevent anaphylactic reactions but apparently reduces their severity. CONCLUSION: For better comparison and precision, the Chemical Abstracts Service number of the respective dye should always be given.
DrugBank Data that Cites this Article
- Drugs
- Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwarePatent BlueRamipril The risk or severity of adverse effects can be increased when Ramipril is combined with Patent Blue. Patent BlueFosinopril The risk or severity of adverse effects can be increased when Fosinopril is combined with Patent Blue. Patent BlueTrandolapril The risk or severity of adverse effects can be increased when Trandolapril is combined with Patent Blue. Patent BlueBenazepril The risk or severity of adverse effects can be increased when Benazepril is combined with Patent Blue. Patent BlueEnalapril The risk or severity of adverse effects can be increased when Enalapril is combined with Patent Blue.